Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Research output: Contribution to journalJournal articleResearchpeer-review

  • Rune Nielsen
  • Hannu Kankaanranta
  • Leif Bjermer
  • Lange, Peter
  • Sofie Arnetorp
  • Morten Hedegaard
  • Anna Stenling
  • Nicole Mittmann
Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler(®)+tiotropium (TIO) HandiHaler(®) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting β2-agonists (ICS/LABA).
Original languageEnglish
JournalRespiratory Medicine
Issue number11
Pages (from-to)1709-21
Number of pages13
Publication statusPublished - Nov 2013

ID: 105585066